{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T23:04:27Z","timestamp":1776812667158,"version":"3.51.2"},"reference-count":12,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transfusion Clinique et Biologique"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1016\/j.tracli.2023.03.003","type":"journal-article","created":{"date-parts":[[2023,3,15]],"date-time":"2023-03-15T22:10:16Z","timestamp":1678918216000},"page":"341-344","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Positive direct antiglobulin tests in cancer patients on immune checkpoint inhibitors: A case series from India"],"prefix":"10.1016","volume":"30","author":[{"given":"Suvro Sankha","family":"Datta","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dibyendu","family":"De","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.tracli.2023.03.003_b0005","doi-asserted-by":"crossref","first-page":"3594","DOI":"10.1182\/blood.2020009016","article-title":"Hematologic complications of immune checkpoint inhibitors","volume":"139","author":"Kroll","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.tracli.2023.03.003_b0010","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1016\/j.clinthera.2015.02.018","article-title":"The next immune-checkpoint inhibitors: PD-1\/PD-L1 blockade in melanoma","volume":"37","author":"Mahoney","year":"2015","journal-title":"Clin Ther"},{"key":"10.1016\/j.tracli.2023.03.003_b0015","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-related adverse events associated with immune checkpoint blockade","volume":"378","author":"Postow","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.tracli.2023.03.003_b0020","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1002\/ajh.25448","article-title":"Clinical and laboratory features of autoimmune hemolytic anemia associated with immune checkpoint inhibitors","volume":"94","author":"Leaf","year":"2019","journal-title":"Am J Hematol"},{"key":"10.1016\/j.tracli.2023.03.003_b0025","doi-asserted-by":"crossref","first-page":"e48","DOI":"10.1016\/S2352-3026(18)30175-3","article-title":"Haematological immune-related adverse events induced by anti-PD-1 or anti-PD-L1 immunotherapy: a descriptive observational study","volume":"6","author":"Delanoy","year":"2019","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.tracli.2023.03.003_b0030","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1001\/jamaoncol.2019.0393","article-title":"Treatment-Related Adverse Events of PD-1 and PD-L1 Inhibitors in Clinical Trials: A Systematic Review and Meta-analysis","volume":"5","author":"Wang","year":"2019","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.tracli.2023.03.003_b0035","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1111\/ejh.13187","article-title":"Autoimmune hemolytic anemia associated with the use of immune checkpoint inhibitors for cancer: 68 cases from the Food and Drug Administration database and review","volume":"102","author":"Tanios","year":"2019","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.tracli.2023.03.003_b0040","doi-asserted-by":"crossref","first-page":"15","DOI":"10.21307\/immunohematology-2019-004","article-title":"Development of red blood cell autoantibodies following treatment with checkpoint inhibitors: a new class of anti-neoplastic, immunotherapeutic agents associated with immune dysregulation","volume":"33","author":"Cooling","year":"2017","journal-title":"Immunohematology"},{"key":"10.1016\/j.tracli.2023.03.003_b0045","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1046\/j.1537-2995.1990.30891020331.x","article-title":"Red cell autoantibodies, multiple immunoglobulin classes, and autoimmune hemolysis","volume":"30","author":"Sokol","year":"1990","journal-title":"Transfusion"},{"key":"10.1016\/j.tracli.2023.03.003_b0050","first-page":"524","article-title":"The clinical implications of IgG subclass in 84 patients with autoimmune hemolytic anemia","volume":"20","author":"Zhang","year":"1999","journal-title":"Zhonghua Xue Ye Xue Za Zhi"},{"key":"10.1016\/j.tracli.2023.03.003_b0055","doi-asserted-by":"crossref","first-page":"11743","DOI":"10.2147\/CMAR.S264166","article-title":"Association Between RBC Antigen Allo-Antibodies and Immune-Related Adverse Events During Immune Checkpoint Inhibitor Treatment for Advanced Cancers","volume":"12","author":"Jain","year":"2020","journal-title":"Cancer Manag Res"},{"key":"10.1016\/j.tracli.2023.03.003_b0060","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.tracli.2022.09.069","article-title":"Real-world data from India on clinical practices in the management of autoimmune haemolytic anaemia: A survey-based cross-sectional assessment","volume":"30","author":"Das","year":"2023","journal-title":"Transfus Clin Biol"}],"container-title":["Transfusion Clinique et Biologique"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1246782023000393?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1246782023000393?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T10:40:43Z","timestamp":1761129643000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1246782023000393"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8]]},"references-count":12,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["S1246782023000393"],"URL":"https:\/\/doi.org\/10.1016\/j.tracli.2023.03.003","relation":{},"ISSN":["1246-7820"],"issn-type":[{"value":"1246-7820","type":"print"}],"subject":[],"published":{"date-parts":[[2023,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Positive direct antiglobulin tests in cancer patients on immune checkpoint inhibitors: A case series from India","name":"articletitle","label":"Article Title"},{"value":"Transfusion Clinique et Biologique","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tracli.2023.03.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Soci\u00e9t\u00e9 fran\u00e7aise de transfusion sanguine (SFTS). Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}